Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biome Australia Ltd ( (AU:BIO) ) has provided an announcement.
Biome Australia Ltd, a specialist in evidence-based probiotics and complementary medicines, partners with global microbiome researchers to develop its Activated Probiotics range, which targets issues such as mood, sleep, bone health, iron malabsorption, mild eczema and IBS. The company focuses on practitioner-only distribution and education to expand the use of natural, research-backed therapies in managing chronic health concerns.
The company has appointed MVAB Audit Pty Ltd as its new external auditor, effective 10 April 2026, following the resignation of its previous auditor, MVAB Assurance, with regulatory consent. Shareholders will be asked to ratify the new auditor’s appointment at Biome Australia’s 2026 annual general meeting, marking a formal transition in the company’s audit oversight framework.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.34 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Ltd is an Australian-based developer and marketer of innovative, evidence-based live biotherapeutics and complementary medicines, distributed locally and internationally. Working with leading microbiome research partners, it has created its flagship Activated Probiotics range, which uses advanced delivery technologies and is sold via practitioner-only channels to support a variety of health conditions.
Average Trading Volume: 229,467
Technical Sentiment Signal: Hold
Current Market Cap: A$76.38M
See more insights into BIO stock on TipRanks’ Stock Analysis page.